10-K: Theravance Biopharma Reports Full Year 2023 Results, Highlights YUPELRI Sales Growth and Ampreloxetine Progress

Theravance Biopharma's 2023 annual report showcases YUPELRI's sales growth and the advancement of ampreloxetine into a new Phase 3 clinical study.

Summary

• Theravance Biopharma's 2023 saw a 9% increase in YUPELRI net sales, reaching $221 million, driven by a 46% growth in hospital volumes.
• The company initiated a new Phase 3 clinical study for ampreloxetine, named CYPRESS, targeting symptomatic neurogenic orthostatic hypotension in MSA patients.
• Theravance repurchased 18.63 million shares in 2023 at an average cost of $10.551 per share, totaling $196.6 million, and since September 2022, repurchased 31.41 million shares for $325.3 million, reducing shares by 37%.
• Research activities, including the inhaled JAK inhibitor program, were discontinued in February 2023, leading to a 17% reduction in headcount.
• Three new independent directors were appointed to the board, and a proposal to declassify the board was approved.
• A Phase 4 study comparing YUPELRI to Spiriva HandiHaler did not meet its primary endpoint, but YUPELRI's safety and efficacy profile remained consistent with previous studies.
• Viatris' Phase 3 study of YUPELRI in China was positive, with plans for a registrational filing in mid-2024.
• The company is eligible for up to $205 million in potential global milestone payments from Viatris, excluding China, and up to $52.5 million related to the China region.
• Royalty Pharma invested up to $40 million in ampreloxetine development in exchange for low single-digit royalties.
• The company sold its economic interest in TRELEGY to Royalty Pharma for $1.1 billion upfront, retaining rights to future milestone payments and outer-year royalties.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive aspects such as YUPELRI's sales growth and the progress of ampreloxetine, the company also reported a net loss and discontinued research activities. The overall tone is cautiously optimistic.

Positives

• YUPELRI experienced significant sales growth and reached all-time high yearly net sales and profitability.
• The initiation of the ampreloxetine Phase 3 study (CYPRESS) marks a significant step in its development.
• The capital return program has reduced the number of outstanding shares by 37%.
• The company has a strong value proposition anchored in its Core Values.
• The company has a strong focus on diversity, equity, and inclusion.

Negatives

• A Phase 4 study comparing YUPELRI to Spiriva HandiHaler did not meet its primary endpoint.
• The discontinuation of research activities led to a 17% reduction in headcount.
• The company reported a net loss of $55.2 million for the year ended December 31, 2023.
• The company is dependent on third-party manufacturers for its products.

Risks

• The company may never achieve or sustain profitability from its operations.
• YUPELRI's acceptance by physicians and patients may not continue to grow.
• Delays in clinical studies or adverse results could harm the business.
• Failure to obtain regulatory approvals would prevent commercialization of product candidates.
• The company faces substantial competition from companies with more resources.
• The company is subject to extensive and ongoing regulation by the FDA.
• The company may face competition from generic versions of its approved products.
• The company depends on third parties in the conduct of its non-clinical and clinical studies.
• The company may not receive Milestone Payments or the revenue expected from the Outer Years Royalty related to TRELEGY.
• The company's business and operations would suffer in the event of significant disruptions of information technology systems or security breaches.

Future Outlook

The company is focused on executing the ampreloxetine Phase 3 study and preparing for the NDA filing process, while also seeking a partnership to continue progression of its inhaled JAK inhibitor program.

Management Comments

• The company is committed to creating/driving shareholder value.
• The company's focus is to deliver medicines that make a difference in people's lives.

Industry Context

The document highlights the competitive landscape for COPD treatments, including nebulized bronchodilators and monoclonal antibodies, and the potential for ampreloxetine to be a first-in-class treatment for MSA patients with symptomatic nOH.

Comparison to Industry Standards

• The document mentions competitors such as Verona Pharma with ensifentrine and Sanofi and Regeneron with Dupixent in the COPD space, indicating a competitive market.
• The document notes that droxidopa is currently the sole product approved for nOH patients, but it has never demonstrated a durable effect on nOH symptoms, suggesting a potential advantage for ampreloxetine if approved.
• The document also mentions that TRELEGY competes with AstraZenecas Breztri Aerosphere and Novartiss Enerzair Breezhaler, highlighting the competitive landscape for triple therapy treatments.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in patent infringement suits against generic companies seeking to market a generic version of YUPELRI.
• The company has settled litigation with some of the generic applicants, granting them a license to market their generic versions of YUPELRI after April 23, 2039.

Stakeholder Impact

• Shareholders have benefited from the capital return program, which reduced the number of outstanding shares.
• Employees were affected by the discontinuation of research activities and the resulting headcount reduction.
• Patients may benefit from the potential approval of ampreloxetine for MSA.

Next Steps

• The company will continue to execute the ampreloxetine Phase 3 study (CYPRESS).
• The company will prepare for the NDA filing process for ampreloxetine.
• The company plans to seek a partnership to continue progression of its inhaled JAK inhibitor program.
• Viatris plans to move forward with a registrational filing for YUPELRI in China in mid-2024.

Key Dates

Keywords

YUPELRI, Ampreloxetine, COPD, MSA, Neurogenic Orthostatic Hypotension, LAMA, Norepinephrine Reuptake Inhibitor, Clinical Study, Orphan Drug Designation, Share Repurchase, TRELEGY, Royalty Pharma, Viatris, FDA, Pharmaceuticals